Compare LGIH & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | EVO |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2013 | 2021 |
| Metric | LGIH | EVO |
|---|---|---|
| Price | $51.17 | $3.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $75.90 | $7.00 |
| AVG Volume (30 Days) | ★ 439.2K | 66.9K |
| Earning Date | 02-17-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.53 | N/A |
| Revenue | ★ $1,788,933,000.00 | $887,396,457.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.60 | $8.52 |
| P/E Ratio | $11.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $39.70 | $2.84 |
| 52 Week High | $97.25 | $4.80 |
| Indicator | LGIH | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 54.06 | 58.79 |
| Support Level | $50.95 | $3.53 |
| Resistance Level | $55.28 | $3.63 |
| Average True Range (ATR) | 3.08 | 0.08 |
| MACD | 0.23 | -0.00 |
| Stochastic Oscillator | 63.63 | 59.46 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company have seven operating segments ( West, Northwest, Central, Midwest, Florida, Southeast and Mid-Atlantic) that it aggregates into five qualifying reportable segment. Majority of the revenue is generated from Central division segment.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.